BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: A Gynecologic Oncology Group Study

British Journal of Cancer

Volumn 108, Issue 6, 2013, Pages 1231-1237

  Lesnock, J L ^a   Darcy, K M ^b,h   Tian, C ^b,i   Deloia, J A ^c   Thrall, M M ^d   Zahn, C ^e   Armstrong, D K ^f   Birrer, M J ^g   Krivak, T C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

ⁱ Precision Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; SURVIVAL RATE;

EID: 84876415689     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.70     Document Type: Article

References (37)

1. Alberts DS, Lui PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130.
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Gynecologic Oncology Group (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
4. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
5. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP (2011) BRCA1 is both prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 123: 492-498.
6. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195.
7. Chetrit A, Hirsch-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S (2008) Effect of BRCA1/2 mutations on long term survival in patients with advanced ovarian cancer; the national Israeli study of ovarian cancer. J Clin Oncol 26: 20-25.
8. Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1-11.
9. Foulkes WD (2006) BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5: 135-142.
10. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845-851.
11. Jazaeri A, Yee C, Sotriou C, Brantley K, Boyd J, Liu E (2002) Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers J Natl Cancer Inst 94: 990-1000.
12. Konstantinopoulos P, Spentzos D, Karlan B, Taniguchi T, Fountzilas E, Francoer N, Levine DA, Cannistra SA (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561.
13. Lage H, Denkert C (2007) Resistance to chemotherapy in ovarian carcinoma. Recent Results Cancer Res 176: 51-1760.
14. Majdak EJ, Debniak J, Milczek T, Cornelise CJ, Devilee P, Emerich J, Jassem J, De Bock GH (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104: 1004-1012.
15. Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, Simone G, Schittulli F, Paradiso A (2009) BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol 24: 69-76.
16. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007.
17. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 226: 66-71.
18. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R (2007) Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 6: 113-119.
19. Pharaoh PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999) Survival in familial BRCA1-associated, BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 59: 868-871.
20. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP (2009) BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 113: 134-142.
21. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13: 7413-7420.
22. Russell PA, Pharoah PD, de Foy K, Ramus SJ, Symmonds I, Wilson A, Scott I, Ponder BA, Gayther SA (2000) Frequent loss of BRCA1mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 87: 317-321.
23. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
24. Sirisabya N, Manchana T, Termrungreunglert W, Triratanachat S, Charuruks N, Tresukosol D (2007) Prevalence of BRCA1 expression in epithelial ovarian cancer: immunohistochemical study. J Med Assoc Thai 90: 9-14.
25. Stordal B, Davey R (2009) A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 9: 354-365.
26. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh R, Goff BA, Welsch P (2009) Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8: 48-54.
27. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68: 2581-2586.
28. Tan D, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Arden-Jones A, Norman A, Kaye SB, Gore ME (2008) "BRCAness" syndrome in ovarian cancer: a case control study describing the clinical features and outcomes of patients with epithelial ovarian cancer associated with BRCa1 and BRCA2 mutations. J Clin Oncol 26: 5530-5536.
29. The Cancer Genome Research Network (2011) Integrated genome analyses of ovarian carcinoma. Nature 474(7353): 609-615.
30. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, Deloia JA (2006) BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 16: 166-171.
31. Turner N, Tutt A, Ashworth A (2004) Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 4: 814-819.
32. Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571-576.
33. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
34. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucett S, Antoniouk O, Glenwood G, Dimitroulakos J (2009) The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 24: 806-815.
35. Wilcox CB, Basal BE, Gallion HH, Strange MA, Deloia JA (2005) Highresolution methylation analysis of the BRCA1 promotor in ovarian tumors. Cancer Genet Cytogenet 159: 114-122.
36. Yang D, Kahn S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
37. Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle response to DNA damage. Cancer Sci 95: 866-871.